Drug Trial Radar · NCT03090659
LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jun 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 2, 2015
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Nanjing Legend Biotech Co.Industry
- Sponsor type
- Industry
- Collaborators
- Second Affiliated Hospital of Xi'an Jiaotong University; Ruijin Hospital; Jiangsu Provincial People's Hospital; Shanghai Changzheng Hospital
- First posted
- Mar 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).
Conditions
- Refractory or Relapsed Multiple Myeloma
Interventions
LCAR-B38M CAR-T cell injectionBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment related adverse events as assessed by CTCAE v4.0Time frame: Day 1-30 days after injection
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.